In vivo imaging of tumor response to therapy using a dual-modality imaging strategy
In vivo imaging of tumor response to therapy using a dual-modality imaging strategy
复制标题
DOI：
10.1002/ijc.21672
复制
发表时间：
2006-06-01
影响因子：
6.4
通讯作者：
Moore, A
中科院分区：
文献类型：
--
作者：
Medarova, Z;Pham, W;Moore, A
由于缺乏专门针对肿瘤的非侵入性成像探针，癌症治疗结果的体内评估受到阻碍。随着化疗药物的不断发展以及评估其在临床环境中有效性的必要性，此类探针的重要性也随之增加。我们最近报道了一种双模态成像探针，专门针对糖基化不足的粘蛋白-1肿瘤特异性抗原（uMUC-1），这是多种肿瘤发生的早期标志之一。该探针由用于 MR 成像的交联超顺磁性氧化铁纳米粒子 (CLIO) 组成，并用 Cy5.5 染料（用于近红外光学荧光成像 (NIRF)）进行修饰，并且具有肽 (EPPT)，专门识别 uMUC-1，附着在纳米粒子的葡聚糖涂层上。在本研究中，我们证明该探针不仅可以检测原位植入的腺癌临床前模型，还可以实时跟踪体内肿瘤对化疗的反应。考虑到新癌症疗法的开发和测试相关的高成本以及对其有效性进行准确、无创评估的需要，我们相信所开发的探针代表了与临床发现相关的有价值的研究工具。 (c) 2005 年 Wiley-Liss, Inc.
In vivo assessment of the outcome of cancer therapy is hampered by the paucity of imaging probes that target tumors specifically and noninvasively. The importance of such probes increases with the continuous development of chemotherapeutics and the necessity to evaluate their effectiveness in a clinical setting. We have recently reported on a dual-modality imaging probe specifically targeting the underglycosylated mucin-1 tumor-specific antigen (uMUC-1), which is one of the early hallmarks of tumorigenesis in a wide variety of tumors. This probe consists of crosslinked superparamagnetic iron oxide nanoparticles (CLIO) for MR imaging, modified with Cy5.5 dye (for near infrared optical fluorescence imaging (NIRF)), and has peptides (EPPT), specifically recognizing uMUC-1, attached to the nanoparticle's dextran coat. In the present study, we demonstrated that this probe could not only detect orthotopically implanted preclinical models of adenocarcinomas but could also track tumor response to chemotherapy in vivo in real time. Considering the high cost associated with the development and testing of new cancer therapeutics and the need for accurate, noninvasive assessment of their effectiveness, we believe that the developed probe represents a valuable research tool relevant to clinical discovery. (c) 2005 Wiley-Liss, Inc.